{"id":2086,"date":"2021-11-29T08:36:06","date_gmt":"2021-11-28T22:36:06","guid":{"rendered":"https:\/\/respiriau.wpengine.com\/?page_id=2086"},"modified":"2024-07-02T15:49:24","modified_gmt":"2024-07-02T05:49:24","slug":"about","status":"publish","type":"page","link":"https:\/\/respiri.co\/au\/about\/","title":{"rendered":"About Respiri"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Respiri Limited
(ASX:RSH, OTCQB:RSHUF)<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t

Respiri Limited is uniquely positioned to revolutionise chronic disease management globally and is focused on the US market, where our suite of evidence-based programs qualify for Current Procedural Terminology (CPT) Code reimbursement. Respiri\u2019s unique medical device when integrated into data-driven programs and enhanced with our clinical expertise ensure patients\u2019 healthcare needs are delivered across the continuum of care. Programs such as Remote Patient Monitoring and Chronic Care Management empower healthcare organisations to act on patient data when needed, not only during scheduled appointments to improve patient outcomes.<\/p>\n

We support our customers to maximise value with a range of customisable programs which meet the health journey needs of patients for all CMS-approved CPT codes, offering providers an opportunity to drive reduced medical events, improved patient health outcomes and reduced healthcare costs while prioritising revenue creation and reimbursement.<\/p>\n

For details on our US programs visit www.respiri.co\/us<\/a><\/strong><\/span><\/p>\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div><\/div>\r\n\t\t<\/section>\r\n\t\t\t\t

\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
About the wheezo\u00ae<\/sup> Medical Device<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t

wheezo\u00ae, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo\u00ae utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri\u2122 app, enabling users to log symptoms and triggers. The wheezo\u00ae system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians.
For details on our US offerings, including wheezo\u00ae, visit www.respiri.co\/us\/wheezo<\/a><\/span><\/p>

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.
wheezo\u00ae is a registered trademark of Respiri Limited<\/p>\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div><\/div>\r\n\t\t<\/section>\r\n\t\t\t\t

\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
The Executive team<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\t

Respiri boasts a world class team consisting of a highly respected Chief Executive Office with a career spanning the healthcare industry, providing valuable experience in medical devices, pharmaceuticals, information systems, technology and sleep disorder solutions. A General Manager of Commercial Operations leading the Commercialisation Team bringing extensive experience in health, successful launches and building teams. An experienced Chief Clinical Officer leading Respiri\u2019s algorithm development and clinical content, and a Chief Technical Officer, with Silicon Valley pedigree, leading the build of the app and data management infrastructure.<\/p>

The entire team is the driving force behind the new SaaS strategy.<\/p>\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
The Board\n<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Nicholas Smedley<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Executive Chairman<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\r\n\t\t\t\t\t\tMr Smedley is an experienced Investment Banker and M&A Advisor, with 14 years\u2019 experience at UBS and KPMG. He has worked on M&A transactions in the UK, Hong Kong, China, and Australia with transactions ranging from the A$9bn defence of WMC Resources through to the investment of $65m into Catch.com.au. Nicholas currently oversees investments in the Property, Aged care, Technology and Medical Technology space. Key areas of expertise include M&A, Debt structuring, Corporate governance and innovation. He holds a Bachelor of Commerce from Monash University.\t\t\t\t\t\t\t<\/div>\r\n\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\n
\n\t\t
\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t\t\"Nicholas-Smedley\"\n\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t<\/div>\n<\/div>\n\n\n\t\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div><\/div>\r\n\t\t<\/section>\r\n\t\t\t\t
\r\n\t\t\t\t\t\t
\r\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Marjan Mikel<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
Chief Executive Officer<\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t